Skip to main content

Table 1 Baseline characteristics of NSTEMI patients stratified according to diabetic status and APG

From: Admission hyperglycemia and adverse outcomes in diabetic and non-diabetic patients with non-ST-elevation myocardial infarction undergoing percutaneous coronary intervention

Characteristic Participants without DM Participants with DM
Group 1 Group 2 Group 3 Group 4
APG <144 mg/dL
n = 470
APG ≥144 mg/dL
n = 184
APG < 180 mg/dL
n = 133
APG ≥180 mg/dL
n = 103
Age (years) 61.0 ± 10.8 62.3 ± 11.9 62.9 ± 10.6 63.1 ± 11.6
Female (%) 87 (18.5)§ 39 (21.2)§ 44 (33.1)*# 38 (36.9)*#
Hypertension (%) 249 (53.0)§ 102 (55.4)§ 98 (73.7)*# 70 (68.0)*#
Hyperlipidemia (%) 93 (19.8) 42 (22.8) 36 (27.1) 31 (30.1)*
Smoking (%) 273 (58.1)§ 104 (56.5)§ 56 (42.1)*# 45 (43.7)*#
Prior MI (%) 54 (11.5) 25 (13.6) 19 (14.3) 15 (14.6)
Prior PCI (%) 40 (8.5)§ 24 (13)§ 30 (22.6)*# 10 (9.7)§
Prior CABG (%) 4 (0.9) 0 (0.0) 2 (1.5) 0 (0.0)
Killip class 3–4 (%) 28 (6.0)# 23 (12.5)* 14 (10.5) 17 (16.5)*
Creatinine (mg/dL) 0.87 ± 0.21 0.87 ± 0.16 0.91 ± 0.24* 0.93 ± 0.29*#
LVEF ≤ 40% (%) 26 (5.5) 18 (9.8) 7 (5.3) 12 (11.7)*
TC (mg/dL) 162.6 ± 40.4 164.1 ± 40.2 160.0 ± 41.1 160.0 ± 44.5
TG (mg/dL) 139.5 ± 61.3 140.9 ± 66.4 141.5 ± 71.4 142.1 ± 65.1
HDL (mg/dL) 40.5 ± 11.8 39.0 ± 9.5 38.5 ± 12.5 39.8 ± 11.8
LDL (mg/dL) 98.6 ± 35.1 99.7 ± 33.8 92.3 ± 37.6 92.4 ± 39.0
Triple vessel disease or LM (%) 196 (41.7)§ 90 (48.9)§ 82 (61.7)*# 66 (64.1)*#
Number of vessels treated 1.45 ± 0.7 1.5 ± 0.6 1.57 ± 0.7 1.54 ± 0.7
Number of stents implanted 2.17 ± 1.3 2.33 ± 1.2 2.14 ± 1.3 2.25 ± 1.0
LAD culprit lesion (%) 203 (43.2) 91 (49.5)§ 44 (33.1)*# 41 (39.8)
TIMI 0/1flow pre‐PCI (%) 153 (32.6) 52 (28.3)§ 67 (50.4)*# 32 (31.1)§
Medication during hospitalization
 Aspirin 467 (99.4) 182 (98.9) 132 (99.2) 102 (99.0)
 Ticlopidine and clopidogrel 467 (99.4) 467 (99.4) 132 (99.2) 102 (99.0)
 Beta-blockers 407 (86.6) 146 (79.3) 116 (87.2) 84 (82.4)
 ACEI and ARB 391 (83.2) 157 (85.3) 116 (87.2) 95 (92.2)
 Statins 468 (99.6) 181 (98.4) 132 (99.2) 100 (98)
 CCB 45 (9.6) 22 (12.0) 13 (12.6) 13 (10.4)
 Oral hypoglycemic agent 0 (0)# § 6 (3.3)*§ 112 (84.2)*# 87 (84.5)*#
 Insulin 0 (0)# § 2 (1.1)*§ 15 (11.3)*# 20 (19.4)*#
 Medication at discharge, n (%) 453 164 120 83
 Aspirin 418 (92.3) 151 (92.1) 112 (93.3) 81 (97.6)
 Ticlopidine and clopidogrel 56 (12.4) 18 (11.0) 13 (10.8) 11 (13.3)
 Beta-blockers 254 (56.1) 108 (65.9) 76 (63.3) 50 (60.2)
 ACEI and ARB 225 (49.7) 85 (51.8) 76 (63.3) 46 (55.4)
 Statins 387 (85.4) 141 (86.0) 101 (84.2) 72 (86.7)
 CCB 65 (14.3) 27 (16.5) 26 (21.7) 17 (20.5)
  1. APG admission plasma glucose, MI myocardial infarction, PCI percutaneous coronary intervention, CABG coronary artery bypass graft, LVEF left-ventricular ejection fraction, TC total cholesterol, TG triglyceride, HDL High density lipoprotein, LDL Low density lipoprotein, LM left main coronary artery, LAD left anterior descending, TIMI thrombolysis in myocardial infarction, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, CCB calcium channel blocker
  2. *P < 0.05, vs. Group 1
  3. # P < 0.05, vs. Group 2
  4. § P < 0.05, vs. Group 3